About Whitecap Biosciences
Whitecap Biosciences was founded in 2015 in the United States. Focus is placed on the biotechnology sector, where therapeutics for ophthalmological conditions are developed. Operations center on compounds such as WB007, an alpha-2 adrenergic agonist used to enhance vision in glaucoma patients, and WB006, targeted at geographic atrophy. Research and development activities are conducted to address these eye-related disorders.
- Headquarter United States
-
Sectors
Healthcare
-
Phone
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Bausch & Lomb
(Jan 13, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Whitecap Biosciences
Detailed funding history for Whitecap Biosciences
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Whitecap Biosciences
Whitecap Biosciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bausch & Lomb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ophthalmic pharmaceuticals and instruments are developed for eye care.
|
Locked | Locked | Locked |
Investor details for Whitecap Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Whitecap Biosciences
Investment portfolio details for Whitecap Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Whitecap Biosciences
Detailed financials for Whitecap Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Whitecap Biosciences Comparisons
Peer comparison for Whitecap Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Whitecap Biosciences
Detailed competitors of Whitecap Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Whitecap Biosciences
Complete news archive for Whitecap Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Whitecap Biosciences
Whitecap Biosciences was founded in 2015.
Whitecap Biosciences is headquartered in United States.
Whitecap Biosciences was founded in 2015 in the United States. Focus is placed on the biotechnology sector, where therapeutics for ophthalmological conditions are developed. Operations center on compounds such as WB007, an alpha-2 adrenergic agonist used to enhance vision in glaucoma patients, and WB006, targeted at geographic atrophy. Research and development activities are conducted to address these eye-related disorders.
Whitecap Biosciences has 1 investor. Key investors include Bausch & Lomb.